Cogent Biosciences, Inc. (COGT) Shareholder Equity
- 2026-06-30: Common Stock, Value, IssuedUSD $171.00K; Additional Paid in Capital, Common StockUSD $1.85B; Accumulated Other Comprehensive Income (Loss), Net of TaxUSD $-770.00K; Retained Earnings (Accumulated Deficit)USD $-1.38B.
- 2026-03-31: Common Stock, Value, IssuedUSD $171.00K; Additional Paid in Capital, Common StockUSD $1.83B; Accumulated Other Comprehensive Income (Loss), Net of TaxUSD $-415.00K; Retained Earnings (Accumulated Deficit)USD $-1.29B.
- 2025-12-31: Common Stock, Value, IssuedUSD $161.00K; Additional Paid in Capital, Common StockUSD $1.73B; Accumulated Other Comprehensive Income (Loss), Net of TaxUSD $355.00K; Retained Earnings (Accumulated Deficit)USD $-1.19B.
- 2025-09-30: Common Stock, Value, IssuedUSD $141.00K; Additional Paid in Capital, Common StockUSD $1.28B; Accumulated Other Comprehensive Income (Loss), Net of TaxUSD $208.00K; Retained Earnings (Accumulated Deficit)USD $-1.09B.
Cogent Biosciences, Inc. Shareholder Equity
Filed components and totals, with each concept and unit kept separate. Components can overlap; they are not added together. Missing disclosures remain (m). Original concept pages retain their detailed breakdowns and history.
| Period end | Common Stock, Value, Issued USD | Additional Paid in Capital, Common Stock USD | Accumulated Other Comprehensive Income (Loss), Net of Tax USD | Retained Earnings (Accumulated Deficit) USD | Stockholders' Equity Attributable to Parent USD | APIC, Share-based Payment Arrangement, Increase for Cost Recognition USD | Treasury Stock, Retired, Cost Method, Amount USD |
|---|---|---|---|---|---|---|---|
| 2026-06-30 | $171.00K | $1.85B | $-770.00K | $-1.38B | $532.39M | 3 month · $17.11M | (m) |
| 2026-03-31 | $171.00K | $1.83B | $-415.00K | $-1.29B | $607.69M | 3 month · $16.91M | (m) |
| 2025-12-31 | $161.00K | $1.73B | $355.00K | $-1.19B | $636.37M | 12 month · $46.08M | (m) |
| 2025-09-30 | $141.00K | $1.28B | $208.00K | $-1.09B | $302.46M | 3 month · $10.60M | (m) |
| 2025-06-30 | $114.00K | $1.05B | $13.00K | $-1.00B | $155.04M | 3 month · $9.72M | (m) |
| 2025-03-31 | $114.00K | $1.04B | $164.00K | $-931.47M | $219.00M | 3 month · $10.01M | (m) |
| 2024-12-31 | $110.00K | $1.00B | $447.00K | $-859.48M | $256.29M | 12 month · $39.74M | (m) |
| 2024-09-30 | $110.00K | $994.61M | $896.00K | $-791.56M | $314.66M | 3 month · $10.36M | (m) |
| 2024-06-30 | $109.00K | $980.11M | $-192.00K | $-720.92M | $373.22M | 3 month · $10.01M | (m) |
| 2024-03-31 | $96.00K | $862.10M | $-39.00K | $-661.97M | $422.33M | 3 month · $9.39M | (m) |
| 2023-12-31 | $86.00K | $801.06M | $246.00K | $-603.62M | $257.80M | 12 month · $30.62M | (m) |
| 2023-09-30 | $86.00K | $792.21M | $-172.00K | $-549.26M | $302.90M | 3 month · $8.76M | (m) |
| 2023-06-30 | $85.00K | $780.01M | $-97.00K | $-493.88M | $348.43M | 3 month · $7.16M | (m) |
| 2023-03-31 | $71.00K | $610.97M | $16.00K | $-449.80M | $223.56M | 3 month · $5.85M | (m) |
| 2022-12-31 | $70.00K | $601.15M | $-104.00K | $-411.21M | $255.74M | 12 month · $18.37M | (m) |
| 2022-09-30 | $70.00K | $595.80M | $-163.00K | $-371.60M | $289.94M | 3 month · $4.62M | (m) |
| 2022-06-30 | $66.00K | $584.45M | (m) | $-336.53M | $319.38M | 3 month · $4.53M | (m) |
| 2022-03-31 | $46.00K | $411.02M | (m) | $-301.61M | $187.86M | 3 month · $4.17M | (m) |
| 2021-12-31 | $44.00K | $399.71M | (m) | $-270.97M | $214.18M | 12 month · $11.43M | (m) |
| 2021-09-30 | $40.00K | $357.86M | (m) | $-246.06M | $197.24M | 3 month · $3.46M | (m) |
| 2021-06-30 | $40.00K | $354.34M | (m) | $-226.98M | $212.80M | 3 month · $2.59M | (m) |
| 2021-03-31 | $37.00K | $342.47M | (m) | $-210.43M | $226.76M | 3 month · $1.52M | (m) |
| 2020-12-31 | $32.00K | $322.45M | (m) | $-198.70M | $234.67M | 12 month · $5.75M | 12 month · $808.00K |
| 2020-09-30 | $11.00K | $165.18M | (m) | $-187.36M | $-22.17M | 3 month · $3.51M | (m) |
| 2020-06-30 | $32.00K | $156.59M | (m) | $-137.38M | $19.24M | 3 month · $870.00K | (m) |
| 2020-03-31 | $31.00K | $155.66M | (m) | $-129.99M | $25.70M | 3 month · $507.00K | 3 month · $808.00K |
| 2019-12-31 | $8.00K | $155.65M | (m) | $-123.89M | $31.76M | 12 month · $3.24M | (m) |
| 2019-09-30 | $30.00K | $154.78M | (m) | $-126.19M | $28.62M | 3 month · $788.00K | (m) |
| 2019-06-30 | $30.00K | $153.99M | (m) | $-114.27M | $39.76M | 3 month · $885.00K | (m) |
| 2019-03-31 | $30.00K | $153.01M | $-2.00K | $-103.75M | $49.29M | 3 month · $726.00K | (m) |
| 2018-12-31 | $30.00K | $152.28M | $-12.00K | $-92.06M | $60.23M | (m) | (m) |
| 2018-09-30 | $30.00K | $150.98M | $-24.00K | $-83.45M | $67.53M | (m) | (m) |
| 2018-06-30 | $30.00K | $149.94M | $-13.00K | $-73.28M | $76.67M | (m) | (m) |
| 2018-03-31 | $10.00K | $2.99M | $-7.00K | $-64.26M | $-61.27M | (m) | (m) |
| 2017-12-31 | $10.00K | $2.50M | $-16.00K | $-51.34M | $-48.85M | (m) | (m) |
| 2016-12-31 | (m) | (m) | (m) | (m) | $-24.70M | (m) | (m) |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Gossamer Bio, Inc. (GOSS) | United States | $5.355B | -0.65 |
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |
| PTC THERAPEUTICS, INC. (PTCT) | United States | $5.199B | -177.07 |
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| Dianthus Therapeutics, Inc. /DE/ (DNTH) | United States | $5.082B | -27.79 |
| Erasca, Inc. (ERAS) | United States | $5.073B | -19.96 |
| Veradermics, Inc (MANE) | United States | $4.839B | |
| Amneal Pharmaceuticals, Inc. (AMRX) | $6.326B | 25.62 | |
| Liquidia Corp (LQDA) | United States | $6.347B | 51.23 |